Michael Amaonye

Verve Therapeutics, Cambridge, MA, USA.

1 publication 2021 – 2021 ORCID
Gene EditingCRISPR-Cas SystemsCells, CulturedAdenineCholesterol, LDL

What does Michael Amaonye research?

Michael Amaonye studies how gene editing can be used to lower cholesterol levels, a key factor in heart disease. He works specifically with a tool called CRISPR, which allows scientists to make precise changes to genes. In his research, he targets a gene known as PCSK9, which plays a significant role in cholesterol production in the liver. By disabling this gene, he has shown that not only is it possible to lower cholesterol dramatically, but this effect can last for an extended period with only a single treatment. This could change the way people manage cholesterol and heart disease, offering a potential alternative to lifelong medication.

Key findings

  • A single CRISPR-based injection into monkeys reduced cholesterol levels by about 60%.
  • The lowered cholesterol levels remained consistent for at least 8 months without any further treatment.
  • This method presents a promising one-time treatment option for patients with high cholesterol instead of relying on daily cholesterol medications.

Frequently asked questions

Does Dr. Amaonye study cholesterol levels?
Yes, Dr. Amaonye researches how to lower cholesterol levels using gene editing.
What treatment methods has Dr. Amaonye researched?
He has researched using CRISPR gene editing to disable the PCSK9 gene, which helps control cholesterol production.
Is Dr. Amaonye's work relevant to heart disease patients?
Yes, his research is highly relevant as it looks for long-term solutions to manage cholesterol, a major factor in heart disease.

Publications in plain English

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.

2021

Nature

Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE +37 more

Plain English
Researchers used a gene-editing tool called CRISPR to permanently disable a gene in monkeys' livers that controls cholesterol production, delivering it through tiny fat particles injected into the bloodstream. After a single injection, the monkeys' cholesterol dropped by about 60% and stayed low for at least 8 months without any additional treatment. This proves that gene editing could offer heart disease patients a one-time treatment instead of taking cholesterol drugs for life.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.